(12) International Application Status Report

Received at International Bureau: 05 December 2019 (05.12.2019)

Information valid as of: 18 June 2020 (18.06.2020)

Report generated on: 01 October 2020 (01.10.2020)

(10) Publication number: (43) Publication date: (26) Publication language:
WO 2020/11327011 June 2020 (11.06.2020) English (EN)

(21) Application number: (22) Filing date: (25) Filing language:
PCT/AU2019/05132504 December 2019 (04.12.2019) English (EN)

(31) Priority number(s): (32) Priority date(s): (33) Priority status:
62/774,974 (US)04 December 2018 (04.12.2018) Priority document received (in compliance with PCT Rule 17.1)
62/885,373 (US)12 August 2019 (12.08.2019) Priority document received (in compliance with PCT Rule 17.1)
62/897,487 (US)09 September 2019 (09.09.2019) Priority document received (in compliance with PCT Rule 17.1)

(51) International Patent Classification:
C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61P 17/06 (2006.01); A61P 17/10 (2006.01); A61P 37/06 (2006.01)

(71) Applicant(s):
CSL INNOVATION PTY LTD [AU/AU]; 45 Poplar Road Parkville, Victoria 3052 (AU) (for all designated states)

(72) Inventor(s):
INGUANTI, Karen Lisa
AIREY, Jolanta
SIDHU, Jagdev
TORTORICI, Michael
YURASZECK, Theresa

(74) Agent(s):
FB RICE PTY LTD; Level 14, 90 Collins Street Melbourne, Victoria 3000 (AU)

(54) Title (EN): METHOD OF TREATING NEUTROPHILIC CONDITIONS
(54) Title (FR): MÉTHODE DE TRAITEMENT D'AFFECTIONS NEUTROPHILES

(57) Abstract:
(EN): The present disclosure relates to a method for reducing circulating neutrophils in a subject without causing sustained grade 3 or grade 4 neutropenia. The present disclosure also relates to methods for treating neutrophilic conditions with an antibody that inhibit G-CSF signalling. In particular, the present disclosure relates to methods of 5 treating neutrophilic dermatoses, such as hidradenitis suppurativa (HS) and palmoplantar pustulosis (PPP).
(FR): La présente invention concerne un procédé permettant de réduire des neutrophiles circulants chez un sujet sans provoquer de neutropénie de grade 3 ou de grade 4. La présente invention concerne également des méthodes de traitement d'affections neutrophiles à l'aide d'un anticorps inhibant la signalisation de G-CSF. En particulier, la présente invention concerne des méthodes de traitement de dermatoses neutrophiles, telles que l'hidradenitis suppurativa (HS) et la pustulose palmoplantaire (PPP).

International search report:
Received at International Bureau: 30 January 2020 (30.01.2020) [AU]

International Report on Patentability (IPRP) Chapter II of the PCT:
Not available

(81) Designated States:
AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
European Patent Office (EPO) : AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
African Intellectual Property Organization (OAPI) : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG
African Regional Intellectual Property Organization (ARIPO) : BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW
Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, RU, TJ, TM